| Year |
Citation |
Score |
| 2023 |
Iglesia MD, Jayasinghe RG, Chen S, Terekhanova NV, Herndon JM, Storrs E, Karpova A, Zhou DC, Al Deen NN, Shinkle AT, Lu RJ, Caravan W, Houston A, Zhao Y, Sato K, ... ... Bose R, et al. Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages. Biorxiv : the Preprint Server For Biology. PMID 37961519 DOI: 10.1101/2023.10.31.565031 |
0.315 |
|
| 2023 |
Sweeney CJ, Hainsworth JD, Bose R, Burris HA, Kurzrock R, Swanton C, Friedman CF, Spigel DR, Szado T, Schulze K, Price R, Malato J, Lo AA, Levy J, Wang Y, et al. MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2202636. PMID 37793085 DOI: 10.1200/JCO.22.02636 |
0.31 |
|
| 2023 |
Cheng X, Sun Y, Highkin M, Vemalapally N, Jin X, Zhou B, Prior JL, Tipton AR, Li S, Iliuk A, Achilefu S, Hagemann IS, Edwards JR, Bose R. Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 -Cyclin D1 axis driving tumorigenesis and drug resistance. Cancer Research. PMID 37272756 DOI: 10.1158/0008-5472.CAN-22-3558 |
0.405 |
|
| 2023 |
Hensing WL, Gerratana L, Clifton K, Medford AJ, Velimirovic M, Shah AN, D'Amico P, Reduzzi C, Zhang Q, Dai CS, Denault EN, Bagegni NA, Opyrchal M, Ademuyiwa FO, Bose R, et al. Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37265453 DOI: 10.1158/1078-0432.CCR-22-3785 |
0.336 |
|
| 2022 |
Chan A, Ruiz-Borrego M, Marx G, Chien AJ, Rugo HS, Brufsky A, Thirlwell M, Trudeau M, Bose R, García-Sáenz JA, Egle D, Pistilli B, Wassermann J, Cheong KA, Schnappauf B, et al. Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer. Breast (Edinburgh, Scotland). 67: 94-101. PMID 36702070 DOI: 10.1016/j.breast.2022.12.003 |
0.334 |
|
| 2022 |
Chudnovsky Y, Kumar RD, Schrock AB, Connelly C, Gowen K, Frampton GM, Erlich RL, Stephens PJ, Miller VA, Ross JS, Ali SM, Bose R. Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2-Targeted Therapy. Jco Precision Oncology. 1: 1-9. PMID 35172500 DOI: 10.1200/PO.16.00037 |
0.306 |
|
| 2022 |
Ma CX, Luo J, Freedman RA, Pluard TJ, Nangia JR, Lu J, Valdez-Albini F, Cobleigh M, Jones JM, Lin NU, Winer EP, Marcom PK, Anderson J, Thomas S, Haas B, ... ... Bose R, et al. The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2 mutated, non-amplified metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35046057 DOI: 10.1158/1078-0432.CCR-21-3418 |
0.374 |
|
| 2021 |
Bose R, Ma CX. Breast Cancer, Mutations, and Overcoming Drug Resistance. The New England Journal of Medicine. 385: 1241-1243. PMID 34551235 DOI: 10.1056/NEJMcibr2110552 |
0.316 |
|
| 2021 |
Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, Hainsworth J, Meric-Bernstam F, Swanton C, Sweeney CJ, Friedman CF, Bose R, Spigel DR, Wang Y, Levy J, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. The Lancet. Oncology. PMID 34339623 DOI: 10.1016/S1470-2045(21)00336-3 |
0.301 |
|
| 2021 |
Ademuyiwa FO, Chen I, Luo J, Rimawi MF, Hagemann IS, Fisk B, Jeffers G, Skidmore ZL, Basu A, Richters M, Ma CX, Weilbaecher K, Davis J, Suresh R, Peterson LL, ... Bose R, et al. Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. Breast Cancer Research and Treatment. PMID 34173924 DOI: 10.1007/s10549-021-06307-3 |
0.306 |
|
| 2021 |
Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, et al. Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2003398. PMID 34077270 DOI: 10.1200/JCO.20.03398 |
0.334 |
|
| 2021 |
Wardley A, Cortes J, Provencher L, Miller K, Chien AJ, Rugo HS, Steinberg J, Sugg J, Tudor IC, Huizing M, Young R, Abramson V, Bose R, Hart L, Chan S, et al. The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer. Breast Cancer Research and Treatment. PMID 33591468 DOI: 10.1007/s10549-021-06109-7 |
0.353 |
|
| 2020 |
Clifton K, Luo J, Tao Y, Saam J, Rich T, Roshal A, Frith A, Rigden C, Ademuyiwa F, Weilbaecher K, Hernandez-Aya L, Peterson LL, Bagegni N, Suresh R, Bose R, et al. Mutation profile differences in younger and older patients with advanced breast cancer using circulating tumor DNA (ctDNA). Breast Cancer Research and Treatment. PMID 33219484 DOI: 10.1007/s10549-020-06019-0 |
0.413 |
|
| 2020 |
Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G, Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y, Kellum A, et al. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 32464281 DOI: 10.1016/J.Annonc.2020.05.012 |
0.439 |
|
| 2020 |
Kurzrock R, Bowles DW, Kang H, Meric-Bernstam F, Hainsworth J, Spigel DR, Bose R, Burris H, Sweeney CJ, Beattie MS, Blotner S, Schulze K, Cuchelkar V, Swanton C. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 31: 412-421. PMID 32067683 DOI: 10.1016/J.Annonc.2019.11.018 |
0.354 |
|
| 2020 |
Ruddy KJ, Trippa L, Hu J, Barry WT, Dang CT, Yardley DA, Isakoff SJ, Valero VV, Faggen MG, Mulvey TM, Bose R, Weckstein DJ, Wolff AC, Reeder-Hayes KE, Rugo HS, et al. Abstract P2-13-02: Chemotherapy-related amenorrhea (CRA) after adjuvant trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT trial) Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P2-13-02 |
0.358 |
|
| 2020 |
Tolaney SM, Trippa L, Barry W, Hu J, Dang C, Yardley D, Isakoff S, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff A, Reeder-Hayes K, Rugo H, et al. Abstract GS1-05: TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT) Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Gs1-05 |
0.353 |
|
| 2019 |
Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. The Lancet. Oncology. PMID 30857956 DOI: 10.1016/S1470-2045(18)30904-5 |
0.449 |
|
| 2019 |
Xi J, Oza A, Thomas S, Ademuyiwa F, Weilbaecher K, Suresh R, Bose R, Cherian M, Hernandez-Aya L, Frith A, Peterson L, Luo J, Krishnamurthy J, Ma CX. Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 17: 141-147. PMID 30787127 DOI: 10.6004/Jnccn.2018.7094 |
0.391 |
|
| 2019 |
Massicano AVF, Lee S, Crenshaw BK, Aweda TA, El Sayed R, Super I, Bose R, Marquez-Nostra BV, Lapi SE. Imaging of HER2 with [Zr]pertuzumab in Response to T-DM1 Therapy. Cancer Biotherapy & Radiopharmaceuticals. PMID 30676778 DOI: 10.1089/Cbr.2018.2654 |
0.391 |
|
| 2019 |
Hernandez-Aya LF, Gao F, Goedegebuure PS, Ma CX, Ademuyiwa FO, Park H, Peterson LL, Bagegni NA, Bose R, Gillanders WE. A randomized phase II study of nab-paclitaxel + durvalumab + neoantigen vaccine versus nab-paclitaxel + durvalumab in metastatic triple-negative breast cancer (mTNBC). Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps1114 |
0.359 |
|
| 2019 |
Barcenas CH, Hurvitz SA, Palma JAD, Bose R, Chan A, Chien AJ, Farrell C, Hunt D, McCulloch L, Kupic A, Tripathy D, Rugo HS. Effect of prophylaxis on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Phase II CONTROL trial. Journal of Clinical Oncology. 37: 548-548. DOI: 10.1200/Jco.2019.37.15_Suppl.548 |
0.335 |
|
| 2019 |
Exman P, Garrido-Castro A, Hughes M, Freedman R, Ma C, Bose R, Cerami E, Wagle N, Barroso-Sousa R, Fitz C, Lindeman N, MacConaill L, Bychkovsky B, Lloyd, Mackichan C, et al. Abstract P4-04-02: Identifying ERBB-2 activating mutations (mts) in HER2 negative tumors for clinical trials – Impact of institute-wide genomic testing and trial matching on trial enrollment in clinical practice Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P4-04-02 |
0.323 |
|
| 2019 |
Delaloge S, Hurvitz S, Chan N, Bose R, Jankowitz R, Thirlwell M, Láng I, Tije At, Trudeau M, Osborne C, Shen Z, Lalla D, Xu F, Hunt D, Olek E, et al. Abstract P2-13-03: The impact of neratinib with or without anti-diarrheal prophylaxis on health-related quality of life in HER2+ early-stage breast cancer: Analyses from the ExteNET and CONTROL trials Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P2-13-03 |
0.395 |
|
| 2019 |
Li S, Maureen H, Primeau TM, Pratt SL, Diala I, Cutler RE, Mann G, Lalani AS, Ma CX, Bose R. Abstract 4527: Patient-derived organoids and xenografts identify neratinib plus HER2 antibody drug conjugate as a synergistic drug combination for HER2 mutated, nonamplified metastatic breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-4527 |
0.424 |
|
| 2018 |
Griffith OL, Spies NC, Anurag M, Griffith M, Luo J, Tu D, Yeo B, Kunisaki J, Miller CA, Krysiak K, Hundal J, Ainscough BJ, Skidmore ZL, Campbell K, Kumar R, ... ... Bose R, et al. Author Correction: The prognostic effects of somatic mutations in ER-positive breast cancer. Nature Communications. 9: 4850. PMID 30429476 DOI: 10.1038/S41467-018-07407-3 |
0.348 |
|
| 2018 |
Griffith OL, Spies NC, Anurag M, Griffith M, Luo J, Tu D, Yeo B, Kunisaki J, Miller CA, Krysiak K, Hundal J, Ainscough BJ, Skidmore ZL, Campbell K, Kumar R, ... ... Bose R, et al. The prognostic effects of somatic mutations in ER-positive breast cancer. Nature Communications. 9: 3476. PMID 30181556 DOI: 10.1038/S41467-018-05914-X |
0.445 |
|
| 2018 |
Dehdashti F, Wu N, Bose R, Naughton MJ, Ma CX, Marquez-Nostra BV, Diebolder P, Mpoy C, Rogers BE, Lapi SE, Laforest R, Siegel BA. Evaluation of [Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer. Breast Cancer Research and Treatment. PMID 29442264 DOI: 10.1007/S10549-018-4696-Z |
0.412 |
|
| 2018 |
Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017753780. PMID 29320312 DOI: 10.1200/Jco.2017.75.3780 |
0.38 |
|
| 2018 |
Xi J, Oza A, Thomas S, Naughton M, Ademuyiwa F, Weilbaecher K, Suresh R, Bose R, Cherian M, Hernandez-Aya L, Frith A, Peterson L, Krishnamurthy J, Ma C. Abstract P5-21-30: Retrospective review of palbociclib (Pal) efficacy and benefit from subsequent treatments following Pal progression in patients (pts) with hormone receptor positive (HR+) and HER2 negative (HER2-) metastatic breast cancer (MBC) Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P5-21-30 |
0.381 |
|
| 2018 |
Li S, Primeau TM, Pratt SL, Harrill KR, Avogadri-Connors F, Lalani AS, Ma CX, Bose R. Abstract 2173: Testing neratinib-containing drug combination regimens on HER2 mutated non-amplified, ER+ breast cancer patient-derived xenografts Tumor Biology. DOI: 10.1158/1538-7445.Am2018-2173 |
0.449 |
|
| 2018 |
Murray EM, Cherian MA, Ma CX, Bose R. HER2 Activating Mutations in Estrogen Receptor Positive Breast Cancer Current Breast Cancer Reports. 10: 41-47. DOI: 10.1007/S12609-018-0265-Z |
0.518 |
|
| 2017 |
Kumar RD, Bose R. Analysis of somatic mutations across the kinome reveals loss-of-function mutations in multiple cancer types. Scientific Reports. 7: 6418. PMID 28743916 DOI: 10.1038/S41598-017-06366-X |
0.435 |
|
| 2017 |
Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, Winer EP, Naughton MJ, Goetz MP, Russell C, Tripathy D, Cobleigh M, Forero A, Pluard TJ, Anders CK, et al. Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Non-amplified Metastatic Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28679771 DOI: 10.1158/1078-0432.Ccr-17-0900 |
0.443 |
|
| 2017 |
Griffith M, Spies NC, Krysiak K, McMichael JF, Coffman AC, Danos AM, Ainscough BJ, Ramirez CA, Rieke DT, Kujan L, Barnell EK, Wagner AH, Skidmore ZL, Wollam A, Liu CJ, ... ... Bose R, et al. CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. Nature Genetics. 49: 170-174. PMID 28138153 DOI: 10.1038/Ng.3774 |
0.333 |
|
| 2017 |
Bryce AH, Kurzrock R, Meric-Bernstam F, Hurwitz H, Hainsworth JD, Spigel DR, Bose R, Swanton C, Burris HA, Guo S, Yoo B, Beattie MS, Tayama D, Sweeney C. Pertuzumab plus trastuzumab for HER2-positive metastatic urothelial cancer (mUC): Preliminary data from MyPathway. Journal of Clinical Oncology. 35: 348-348. DOI: 10.1200/Jco.2017.35.6_Suppl.348 |
0.41 |
|
| 2017 |
Hurwitz H, Raghav KPS, Burris HA, Kurzrock R, Sweeney C, Meric-Bernstam F, Vanderwalde AM, Spigel DR, Bose R, Fakih M, Swanton C, Guo S, Bernaards C, Beattie MS, Sommer N, et al. Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway. Journal of Clinical Oncology. 35: 676-676. DOI: 10.1200/Jco.2017.35.4_Suppl.676 |
0.422 |
|
| 2017 |
Javle MM, Hainsworth JD, Swanton C, Burris HA, Kurzrock R, Sweeney C, Meric-Bernstam F, Spigel DR, Bose R, Guo S, Bernaards C, Beattie MS, Scappaticci FA, Hurwitz H. Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway. Journal of Clinical Oncology. 35: 402-402. DOI: 10.1200/Jco.2017.35.4_Suppl.402 |
0.494 |
|
| 2017 |
D'souza A, Shishedo S, Spicer DV, Welter L, Jiang Y, Hyman DM, Solit DB, Ma CX, Bose R, Cutler RE, Eli L, Hicks JB, Kuhn P, Lu JM. Circulating tumor cells and genomic profiling of patients with ERBB2 mutant, HER2 non-amplified metastatic breast cancer treated with neratinib. Journal of Clinical Oncology. 35: e12554-e12554. DOI: 10.1200/Jco.2017.35.15_Suppl.E12554 |
0.47 |
|
| 2017 |
Hainsworth JD, Bose R, Sweeney C, Meric-Bernstam F, Hurwitz H, Swanton C, Burris HA, Kurzrock R, Yoo B, Beattie MS, Gupta R, Patel RD, Schulze K, Spigel DR. Targeted therapy for non-small cell lung cancer (NSCLC) with HER2, BRAF, or hedgehog alterations: Interim data from MyPathway. Journal of Clinical Oncology. 35: 9073-9073. DOI: 10.1200/Jco.2017.35.15_Suppl.9073 |
0.428 |
|
| 2017 |
Kurzrock R, Meric-Bernstam F, Hurwitz H, Hainsworth JD, Spigel DR, Bose R, Swanton C, Burris HA, Sweeney C, Yoo B, Beattie MS, Patel R, Schulze K, Lam ET. Targeted therapy for advanced salivary cancer with HER2 or hedgehog alterations: Interim data from MyPathway. Journal of Clinical Oncology. 35: 6086-6086. DOI: 10.1200/Jco.2017.35.15_Suppl.6086 |
0.456 |
|
| 2017 |
Ma C, Bose R, Gao F, Freedman R, Telli M, Kimmick G, Winer E, Naughton M, Goetz M, Russell C, Tripathy D, Cobleigh M, Forero A, Pluard T, Anders C, et al. Abstract CT011: Circulating tumor DNA (ctDNA) sequencing forHER2mutation (HER2mut) screening and response monitoring to neratinib in metastatic breast cancer (MBC) Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct011 |
0.382 |
|
| 2016 |
Keppel TR, Sarpong K, Murray EM, Monsey J, Zhu J, Bose R. Biophysical Evidence for Intrinsic Disorder in the C-terminal Tails of the EGFR and HER3 Receptor Tyrosine Kinases. The Journal of Biological Chemistry. PMID 27872189 DOI: 10.1074/Jbc.M116.747485 |
0.407 |
|
| 2016 |
Kumar RD, Swamidass SJ, Bose R. Unsupervised detection of cancer driver mutations with parsimony-guided learning. Nature Genetics. PMID 27618449 DOI: 10.1038/Ng.3658 |
0.406 |
|
| 2016 |
Ross JS, Gay LM, Wang K, Ali SM, Chumsri S, Elvin JA, Bose R, Vergilio JA, Suh J, Yelensky R, Lipson D, Chmielecki J, Waintraub S, Leyland-Jones B, Miller VA, et al. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies. Cancer. PMID 27284958 DOI: 10.1002/Cncr.30102 |
0.469 |
|
| 2016 |
Laforest R, Lapi SE, Oyama R, Bose R, Tabchy A, Marquez-Nostra BV, Burkemper J, Wright BD, Frye J, Frye S, Siegel BA, Dehdashti F. [(89)Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 27146421 DOI: 10.1007/S11307-016-0951-Z |
0.372 |
|
| 2016 |
Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G, Lee SC, Mehta AO, Kim SB, Bachelot T, Goswami C, Deo S, Bose R, Wong A, Xu F, et al. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial. Jama Oncology. PMID 27078022 DOI: 10.1001/Jamaoncol.2016.0237 |
0.441 |
|
| 2016 |
Ma CX, Bose R, Ellis MJ. Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer. Advances in Experimental Medicine and Biology. 882: 125-54. PMID 26987533 DOI: 10.1007/978-3-319-22909-6_5 |
0.43 |
|
| 2016 |
Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D, Fornili M, Fumagalli D, Brown D, Rothé F, Vincent D, Kheddoumi N, Rouas G, Majjaj S, Brohée S, Van Loo P, ... ... Bose R, et al. Genomic Characterization of Primary Invasive Lobular Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26926684 DOI: 10.1200/Jco.2015.64.0334 |
0.496 |
|
| 2016 |
Hurwitz H, Hainsworth JD, Swanton C, Perez EA, Sweeney C, Burris HA, Spigel D, Meric-Bernstam F, Strickland DK, Leon L, Brammer M, Beattie MS, Bose R. Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors. Journal of Clinical Oncology. 34: 653-653. DOI: 10.1200/Jco.2016.34.4_Suppl.653 |
0.38 |
|
| 2016 |
Bose R, Ali S, Jain N, Gowen K, Bertotti A, Murray E, Ross JS, Beattie MS, Hurwitz H, Hainsworth JD. Frequency of HER2 mutations and amplification in GI malignancies and ability of pertuzumab to overcome neuregulin1 mediated drug resistance to a HER2 tyrosine kinase inhibitor in colon cancer. Journal of Clinical Oncology. 34: 630-630. DOI: 10.1200/Jco.2016.34.4_Suppl.630 |
0.471 |
|
| 2016 |
Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris HA, Bose R, Guo S, Bernaards C, Beattie MS, Stein A, Brammer M, Kurzrock R. Targeted therapy for advanced solid tumors based on molecular profiles: Early results from MyPathway, an open-label, phase IIa umbrella basket study. Journal of Clinical Oncology. 34: LBA11511-LBA11511. DOI: 10.1200/Jco.2016.34.18_Suppl.Lba11511 |
0.387 |
|
| 2016 |
Ma CX, Bose R, Gao F, Freedman RA, Pegram MD, Blackwell K, Bedard PL, Hayes DF, Goetz MP, Niravath PA, Russell CA, Tripathy D, Cobleigh MA, Forero A, Pluard TJ, et al. Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2mut MBC). Journal of Clinical Oncology. 34: 516-516. DOI: 10.1200/Jco.2016.34.15_Suppl.516 |
0.45 |
|
| 2015 |
Zabransky DJ, Yankaskas CL, Cochran RL, Wong HY, Croessmann S, Chu D, Kavuri SM, Red Brewer M, Rosen DM, Dalton WB, Cimino-Mathews A, Cravero K, Button B, Kyker-Snowman K, Cidado J, ... ... Bose R, et al. HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proceedings of the National Academy of Sciences of the United States of America. PMID 26508629 DOI: 10.1073/Pnas.1516853112 |
0.455 |
|
| 2015 |
Ben-Baruch NE, Bose R, Kavuri SM, Ma CX, Ellis MJ. HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 1061-4. PMID 26358790 DOI: 10.6004/Jnccn.2015.0131 |
0.547 |
|
| 2015 |
Kavuri SM, Jain N, Galimi F, Cottino F, Leto SM, Migliardi G, Searleman AC, Shen W, Monsey J, Trusolino L, Jacobs SA, Bertotti A, Bose R. HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment. Cancer Discovery. 5: 832-41. PMID 26243863 DOI: 10.1158/2159-8290.Cd-14-1211 |
0.497 |
|
| 2015 |
Kumar RD, Searleman AC, Swamidass SJ, Griffith OL, Bose R. Statistically Identifying Tumor Suppressors and Oncogenes from Pan-Cancer Genome Sequencing Data. Bioinformatics (Oxford, England). PMID 26209800 DOI: 10.1093/Bioinformatics/Btv430 |
0.383 |
|
| 2015 |
Kovacs E, Das R, Wang Q, Collier TS, Cantor A, Huang Y, Wong K, Mirza A, Barros T, Grob P, Jura N, Bose R, Kuriyan J. Analysis of the role of the C-terminal tail in the regulation of the epidermal growth factor receptor. Molecular and Cellular Biology. PMID 26124280 DOI: 10.1128/Mcb.00248-15 |
0.643 |
|
| 2015 |
Awada A, Colomer R, Bondarenko I, Inoue K, Badwe RA, Demetriou G, Wang X, Smirnov V, Lee S, Mehta AO, Kim S, Shen Z, Bachelot TD, Goswami C, Deo SVS, ... Bose R, et al. Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT). Journal of Clinical Oncology. 33: 610-610. DOI: 10.1200/Jco.2015.33.15_Suppl.610 |
0.392 |
|
| 2015 |
Wagle N, Lin NU, Richardson AL, Leshchiner I, Mayer IA, Forero-Torres A, Hobday TJ, Dees EC, Nanda R, Rimawi MF, Guo H, Barry WT, Bose R, Shen W, Wolff AC, et al. Abstract PD3-5: Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003 Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Pd3-5 |
0.422 |
|
| 2015 |
Kavuri SM, Jain N, Galimi F, Cottino F, Searleman AC, Shen W, Trusolino L, Jacobs SA, Bertotti A, Bose R. Abstract 132: HER2 activating mutations are potential targets for colorectal cancer treatment Cancer Research. 75: 132-132. DOI: 10.1158/1538-7445.Am2015-132 |
0.494 |
|
| 2015 |
Zoppoli G, Gundem G, Pruneri G, Larsimon D, Fornili M, Fumagalli D, Brown D, Salgado R, Brussel TV, Lambrechts D, Bose R, Metzger O, Galant C, Bertucci F, Piccart M, et al. A01*Genomic hallmarks of invasive lobular breast carcinoma and their clinical relevance Annals of Oncology. 26. DOI: 10.1093/Annonc/Mdv336.01 |
0.307 |
|
| 2014 |
Searleman AC, Iliuk AB, Collier TS, Chodosh LA, Tao WA, Bose R. Tissue phosphoproteomics with PolyMAC identifies potential therapeutic targets in a transgenic mouse model of HER2 positive breast cancer. Electrophoresis. 35: 3463-9. PMID 24723360 DOI: 10.1002/Elps.201400022 |
0.659 |
|
| 2013 |
Tabchy A, Ma CX, Bose R, Ellis MJ. Incorporating genomics into breast cancer clinical trials and care. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6371-9. PMID 24298067 DOI: 10.1158/1078-0432.Ccr-13-0837 |
0.412 |
|
| 2013 |
Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, He X, Liu S, Hoog J, Lu C, Ding L, Griffith OL, Miller C, Larson D, Fulton RS, ... ... Bose R, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Reports. 4: 1116-30. PMID 24055055 DOI: 10.1016/J.Celrep.2013.08.022 |
0.422 |
|
| 2013 |
Collier TS, Diraviyam K, Monsey J, Shen W, Sept D, Bose R. Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface. The Journal of Biological Chemistry. 288: 25254-64. PMID 23843458 DOI: 10.1074/Jbc.M113.474882 |
0.691 |
|
| 2013 |
Kumar RD, Chang LW, Ellis MJ, Bose R. Prioritizing Potentially Druggable Mutations with dGene: An Annotation Tool for Cancer Genome Sequencing Data. Plos One. 8: e67980. PMID 23826350 DOI: 10.1371/Journal.Pone.0067980 |
0.409 |
|
| 2013 |
Bose R. A neu view of invasive lobular breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3331-3. PMID 23714731 DOI: 10.1158/1078-0432.Ccr-13-1031 |
0.491 |
|
| 2013 |
Goncalves R, Bose R. Using multigene tests to select treatment for early-stage breast cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 11: 174-82; quiz 182. PMID 23411384 DOI: 10.6004/Jnccn.2013.0025 |
0.466 |
|
| 2013 |
Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Goel N, Aronson AB, Li S, Ma CX, Ding L, Mardis ER, Ellis MJ. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discovery. 3: 224-37. PMID 23220880 DOI: 10.1158/2159-8290.Cd-12-0349 |
0.498 |
|
| 2013 |
Boyer AP, Collier TS, Vidavsky I, Bose R. Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancers. Molecular & Cellular Proteomics : McP. 12: 180-93. PMID 23105007 DOI: 10.1074/Mcp.M112.020115 |
0.677 |
|
| 2013 |
Ellis MJ, Li S, Shen D, Ding L, Crowder R, Shao J, Goncalves R, Tao Y, Luo J, Prat A, Liu W, Gonzalez-Angulo AM, Liu S, McMichael JF, Miller C, ... ... Bose R, et al. Abstract LB-265: Patient-derived xenografts from advanced luminal-type breast cancer: insights into endocrine therapy resistance. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-265 |
0.365 |
|
| 2013 |
Li S, Shen D, Li D, Yu T, Luo J, Hoog J, McMichael J, Miller C, Larson D, Bose R, Fulton B, Wilson R, Perou C, Mardis E, Ellis M. Abstract LB-236: Patient derived xenografts as high-fidelity genomic models for advanced breast cancer. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-236 |
0.43 |
|
| 2012 |
Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, Maher CA, Fulton R, Fulton L, Wallis J, Chen K, Walker J, McDonald S, Bose R, Ornitz D, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 150: 1121-34. PMID 22980976 DOI: 10.1016/J.Cell.2012.08.024 |
0.369 |
|
| 2012 |
Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, ... ... Bose R, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 486: 353-60. PMID 22722193 DOI: 10.1038/Nature11143 |
0.487 |
|
| 2012 |
Ferrando IM, Chaerkady R, Zhong J, Molina H, Jacob HK, Herbst-Robinson K, Dancy BM, Katju V, Bose R, Zhang J, Pandey A, Cole PA. Identification of targets of c-Src tyrosine kinase by chemical complementation and phosphoproteomics. Molecular & Cellular Proteomics : McP. 11: 355-69. PMID 22499769 DOI: 10.1074/Mcp.M111.015750 |
0.351 |
|
| 2012 |
Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Goiffon RJ, Wallis JW, Goldstein TC, Chen K, Allred DC, Leitch AM, Olson JA, Ota DM, Watson M, Piwnica-Worms D, ... Bose R, et al. Whole genome sequencing to characterize luminal-type breast cancer. Journal of Clinical Oncology. 30: 503-503. DOI: 10.1200/Jco.2012.30.15_Suppl.503 |
0.448 |
|
| 2012 |
Ellis MJ, Li D, Shen D, Luo J, Suman VJ, Wallis JW, Tine BAV, Hoog J, Crowder RJ, Snider JE, Ballman K, Chen K, Koboldt DC, Schierding WS, McMichael JF, ... ... Bose R, et al. Abstract LB-423: Whole genome comparisons of pre- and post- aromatase inhibitor treatment in estrogen receptor positive breast cancer Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-423 |
0.395 |
|
| 2012 |
Bose R, Kavuri S, Searleman A, Shen W, Shen D, Koboldt D, Monsey J, Li S, Ding L, Mardis E, Ellis M. Abstract S5-6: Activating HER2 mutations in HER2 gene amplification negative breast cancers. Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-S5-6 |
0.496 |
|
| 2011 |
Ozgül RK, Siemiatkowska AM, Yücel D, Myers CA, Collin RW, Zonneveld MN, Beryozkin A, Banin E, Hoyng CB, van den Born LI, Bose R, Shen W, Sharon D, Cremers FP, et al. Exome sequencing and cis-regulatory mapping identify mutations in MAK, a gene encoding a regulator of ciliary length, as a cause of retinitis pigmentosa. American Journal of Human Genetics. 89: 253-64. PMID 21835304 DOI: 10.1016/J.Ajhg.2011.07.005 |
0.378 |
|
| 2011 |
Zhang H, Shen W, Rempel D, Monsey J, Vidavsky I, Gross ML, Bose R. Carboxyl-group footprinting maps the dimerization interface and phosphorylation-induced conformational changes of a membrane-associated tyrosine kinase. Molecular & Cellular Proteomics : McP. 10: M110.005678. PMID 21422241 DOI: 10.1074/Mcp.M110.005678 |
0.398 |
|
| 2011 |
Ellis MJ, Ding L, Shen D, Wallis J, Suman V, Luo J, Tao Y, Hoog J, Davies S, Lin L, Perou C, Tine BV, Bose R, Chang LW, Chen K, et al. Abstract LB-87: Analysis of luminal-type breast cancer by massively parallel sequencing Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-87 |
0.431 |
|
| 2011 |
Boyer AP, Alvarez S, Boyne M, Hicks L, Bose R. Abstract 5126: Development of a high throughput quantitative phosphoproteomic method to study trastuzumab resistance Cancer Research. 71: 5126-5126. DOI: 10.1158/1538-7445.Am2011-5126 |
0.468 |
|
| 2010 |
Monsey J, Shen W, Schlesinger P, Bose R. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system. The Journal of Biological Chemistry. 285: 7035-44. PMID 20022944 DOI: 10.1074/Jbc.M109.096032 |
0.432 |
|
| 2010 |
Monsey J, Shen W, Schlesinger PS, Bose R. Abstract 3122: Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstitutedin vitrosystem Cancer Research. 70: 3122-3122. DOI: 10.1158/1538-7445.Am10-3122 |
0.442 |
|
| 2009 |
Bose R, Zhang X. The ErbB kinase domain: structural perspectives into kinase activation and inhibition. Experimental Cell Research. 315: 649-58. PMID 18761339 DOI: 10.1016/J.Yexcr.2008.07.031 |
0.419 |
|
| 2008 |
Qiu C, Tarrant MK, Choi SH, Sathyamurthy A, Bose R, Banjade S, Pal A, Bornmann WG, Lemmon MA, Cole PA, Leahy DJ. Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Structure (London, England : 1993). 16: 460-7. PMID 18334220 DOI: 10.1016/J.Str.2007.12.016 |
0.404 |
|
| 2008 |
Mathivanan S, Ahmed M, Ahn NG, Alexandre H, Amanchy R, Andrews PC, Bader JS, Balgley BM, Bantscheff M, Bennett KL, Björling E, Blagoev B, Bose R, Brahmachari SK, Burlingame AS, et al. Human Proteinpedia enables sharing of human protein data. Nature Biotechnology. 26: 164-7. PMID 18259167 DOI: 10.1038/Nbt0208-164 |
0.447 |
|
| 2007 |
Zhang X, Pickin KA, Bose R, Jura N, Cole PA, Kuriyan J. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature. 450: 741-4. PMID 18046415 DOI: 10.1038/Nature05998 |
0.41 |
|
| 2006 |
Bose R, Holbert MA, Pickin KA, Cole PA. Protein tyrosine kinase-substrate interactions. Current Opinion in Structural Biology. 16: 668-75. PMID 17085043 DOI: 10.1016/J.Sbi.2006.10.012 |
0.346 |
|
| 2006 |
Bose R, Molina H, Patterson AS, Bitok JK, Periaswamy B, Bader JS, Pandey A, Cole PA. Phosphoproteomic analysis of Her2/neu signaling and inhibition. Proceedings of the National Academy of Sciences of the United States of America. 103: 9773-8. PMID 16785428 DOI: 10.1073/Pnas.0603948103 |
0.442 |
|
| Show low-probability matches. |